AMAG Pharmaceuticals, Inc. (AMAG) Forms $19.90 Double Bottom; Lrad (LRAD) SI Increased By 24.11%

Lrad Corporation (NASDAQ:LRAD) had an increase of 24.11% in short interest. LRAD’s SI was 83,400 shares in February as released by FINRA. Its up 24.11% from 67,200 shares previously. With 62,200 avg volume, 1 days are for Lrad Corporation (NASDAQ:LRAD)’s short sellers to cover LRAD’s short positions. The SI to Lrad Corporation’s float is 0.33%. The stock decreased 5.24% or $0.12 during the last trading session, reaching $2.17. About 67,437 shares traded or 3.61% up from the average. LRAD Corporation (NASDAQ:LRAD) has risen 6.40% since February 27, 2017 and is uptrending. It has underperformed by 10.30% the S&P500.

AMAG Pharmaceuticals, Inc. (AMAG) formed double bottom with $18.31 target or 8.00% below today’s $19.90 share price. AMAG Pharmaceuticals, Inc. (AMAG) has $703.95 million valuation. The stock increased 1.27% or $0.25 during the last trading session, reaching $19.9. About 871,706 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since February 27, 2017 and is uptrending. It has underperformed by 13.70% the S&P500.

LRAD Corporation designs, develops, and commercializes directed sound technologies and products in North and South America, Europe, the Middle East, and Asia. The company has market cap of $69.98 million. It develops directed acoustic products that beam, focus, and control sound over short and long distances. It currently has negative earnings. The firm offers directional and omnidirectional sound products, which are used for communication and deterring threats over distances.

Investors sentiment increased to 1.44 in Q3 2017. Its up 0.35, from 1.09 in 2017Q2. It improved, as 21 investors sold AMAG Pharmaceuticals, Inc. shares while 43 reduced holdings. 35 funds opened positions while 57 raised stakes. 39.98 million shares or 4.47% less from 41.85 million shares in 2017Q2 were reported. Proshare Limited Liability invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Falcon Point Capital Ltd Liability invested in 839,477 shares. Tiaa Cref Inv Mngmt Ltd Limited Liability Company reported 157,438 shares. Alps Advsr holds 34,752 shares. Fincl Bank Of America Corp De reported 0% stake. Cubist Systematic Strategies Ltd Limited Liability Company has invested 0.01% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Mason Street Lc reported 0% stake. Pub Employees Retirement Association Of Colorado invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Cornerstone Capital Lc stated it has 12,351 shares or 0% of all its holdings. Northern Trust stated it has 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Bridgeway Cap Mgmt Inc reported 75,500 shares. Alliancebernstein Lp owns 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 60,353 shares. Citigroup holds 80,028 shares. Moreover, First Midwest Bancorporation Tru Division has 0.1% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Riverhead Mngmt Limited Liability owns 3,383 shares for 0% of their portfolio.

Among 14 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 have Buy rating, 1 Sell and 9 Hold. Therefore 29% are positive. AMAG Pharmaceuticals had 41 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank on Wednesday, November 4 with “Hold”. Piper Jaffray maintained it with “Hold” rating and $15.0 target in Thursday, January 18 report. Raymond James initiated the stock with “Outperform” rating in Tuesday, September 1 report. As per Thursday, August 11, the company rating was maintained by Jefferies. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Buy” rating by Jefferies on Tuesday, August 18. The rating was maintained by Jefferies with “Buy” on Wednesday, August 16. Needham downgraded AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Wednesday, January 11 to “Hold” rating. The firm has “Buy” rating given on Thursday, February 15 by Janney Capital. The firm has “Mkt Perform” rating given on Tuesday, January 10 by Leerink Swann. The stock has “Hold” rating by Cantor Fitzgerald on Monday, July 24.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: